Navigation Links
Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
Date:4/8/2008

SOUTH SAN FRANCISCO, Calif., April 8, 2008 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the discovery and development of monoclonal antibody therapeutics (MAbs) for cancer announced today that it has entered into an agreement with Monogram Biosciences, Inc., under which Monogram will evaluate selected Raven monoclonal antibodies for use with its VeraTag(TM) technology for diagnosis of cancer.

"Raven's extensive library of antibody candidates that bind to antigens present at high levels on tumor tissue can be developed as therapeutic and diagnostic antibodies," stated George Schreiner, M.D., Ph.D., chief executive officer of Raven biotechnologies. "Through our collaboration with Monogram we hope ultimately to accelerate the development of targeted oncology therapeutics."

The Raven technology platform has generated well-characterized, high-affinity monoclonal antibodies to proteins on the cell surface that can be used to quickly identify and validate targets. The platform has delivered an extensive library of antibodies targeting novel and recognized antigens. Raven is initially focusing on antibody-based therapeutics targeting lung, colon, pancreatic, prostate, breast, and ovarian cancer.

Monogram Biosciences' VeraTag(TM) technology can accelerate the development of targeted therapeutics, improve clinical trial design and results, clarify and individualize the selection of medications, and optimize outcomes for patients with cancer and other serious diseases.

About Raven biotechnologies

Raven biotechnologies, inc. (http://www.ravenbio.com) is a privately held biotechnology company focused on the development of monoclonal antibody therapeutics for treating cancer. Raven's lead product candidate, RAV12, targets adenocarcinomas and is in clinical development for the treatment of gastrointestinal and other cancers. Raven's discovery process si
'/>"/>

SOURCE Raven biotechnologies, inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim
2. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
3. First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
4. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
5. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
6. Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations
7. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
8. Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO
9. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
10. VaxGen and Raven Terminate Merger Agreement
11. Raven biotechnologies and Bioprocessing Technology Institute Announce Collaboration to Advance Discovery of Stem Cell Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... Editor Note: For more information about this ... ago, Analysts Review released new research updates concerning several important ... SSH ), Synergetics USA (NASDAQ: ... Spectranetics (NASDAQ: SPNC ), and Thoratec (NASDAQ: ... for investors, to hear about what matters - proudly employing ...
(Date:3/2/2015)... Massachusetts (PRWEB) March 02, 2015 Outside ... services, today announced the addition of Debbie Casey as ... capabilities in the healthcare space. , Debbie ... most of which with Fresenius Medical Care North America ... leverage her extensive experience to work with Outside GC’s ...
(Date:2/27/2015)... , Feb. 27, 2015  Pharmacyclics, Inc. ... longer-term toxicology studies for its newly developed Bruton,s ... RA, have been completed. The results of these ... Food and Drug Administration. The feedback received from ... the ongoing first-in-human study. Additional preclinical work is ...
(Date:2/27/2015)... , Feb. 27, 2015 Bionomics Limited ... the DisrupTOR-1 trial of BNC105 in patients with metastatic ... Orlando, Florida . The data will ... the City of Hope Comprehensive Cancer Center in ... The new data identifies Ferritin and IL-8 ...
Breaking Biology Technology:Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 2Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 3Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 4Outside GC Expands Healthcare Team 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5
... YORK, March 7, 2011 Reportlinker.com announces ... available in its catalogue: ... Japan - Emerging Opportunities and Business Expansion ... http://www.reportlinker.com/p0365328/The-2011-Blood-Banking-Market-US-Europe-Japan---Emerging-Opportunities-and-Business-Expansion-Strategies-for-Suppliers.html During the next ...
... 2011 Champions Biotechnology, Inc. (OTC: CSBR), today announced its ... 2011. Fiscal 2011 Third Quarter Financial Highlights ... an increase of 278% compared to the third quarter of ... excluding stock based compensation of $796,000* Net ...
... the world of nanoparticles has now become a possibility, thanks ... UCSB research team has developed a new instrument capable of ... tens of nanometers. The study will be published on line ... the April print issue of the journal. "This ...
Cached Biology Technology:Reportlinker Adds The 2011 Blood Banking Market: US, Europe, Japan - Emerging Opportunities and Business Expansion Strategies for Suppliers 2Champions Biotechnology Reports Fiscal 2011 Third Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2011 Third Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2011 Third Quarter Financial Results 4Champions Biotechnology Reports Fiscal 2011 Third Quarter Financial Results 5Champions Biotechnology Reports Fiscal 2011 Third Quarter Financial Results 6New instrument keeps an 'eye' on nanoparticles 2
(Date:2/5/2015)... January 28, 2015 New Market ... And Segment Forecasts To 2020 has Been Added to ... market is expected to reach USD 5.10 billion by ... Research, Inc. IR cameras help identify the site of ... to witness surging demand in medical imaging applications. They ...
(Date:1/22/2015)... 22, 2015 Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) ... Global Market Overview" report to their offering. , ... ensure that an individual is who she/he is claiming to ... of a person,s unique physical characteristics, such as fingerprint, hand ...
(Date:1/22/2015)... 15, 2015  BellBrook Labs, a leader in high ... launch of a TR-FRET (time resolved Forster resonance ... Assay, a high throughput screening assay for glycosyltransferases ... allow for sensitive detection of hundreds of human ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... microbes living in their roots, according to new research at ... carbon cycle that is vital to life on earth. ... to make sugar by combining water with carbon dioxide from ... scientists in the Universitys Department of Biology discovered that some ...
... a mucky Florida swamp have given scientists a window ... 15 million to 130 million years old. Scientists ... Natural History in Berlin made the landmark discovery that ... unwittingly swim into resin flowing down into the water ...
... Bats are the most vocal mammals other than ... outings could lead to better treatments for human speech ... of bats native to Central Texas fly overhead each ... frequencies too high for humans to hear. Texas ...
Cached Biology News:Hungry microbes share out the carbon in the roots of plants 2Scientists find how amber becomes death trap for watery creatures 2Scientists find how amber becomes death trap for watery creatures 3Researchers studying how singing bats communicate 2
TRIS-EDTA based buffer prepared from RNase-free water suitable for storage and dilution of siRNA, pH 8, store at 4 C ...
Request Info...
Agarose-LE, 250 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
IC50: 3 ng/ml · Limit of detection: 0.9 ng/ml...
Biology Products: